HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vague, P. Articles by Draeger, E. Search for Related Content PubMed PubMed Citation Articles by Vague, P. Articles by Draeger, E. Social Bookmarking                What's this?

Insulin Detemir Is Associated With More Predictable Glycemic Control and Reduced Risk of Hypoglycemia Than NPH Insulin in Patients With Type 1 Diabetes on a Basal-Bolus Regimen With Premeal Insulin Aspart

¹ Hôpital de la Timone, Service Nutrition Endocrinologie et Maladies Metabolique, Marseilles, France
² Hotel Dieu, Service de Diabétologie, Paris, France
³ Hjertelaget Research Foundation, Stavanger, Norway
⁴ Department of Endocrinology, University of Antwerp, Antwerp, Belgium
⁵ St. Franciscus Gasthuis, Rotterdam, the Netherlands
⁶ Novo Nordisk A/S, Gladsaxe, Denmark.

OBJECTIVE—Insulin detemir is a soluble basal insulin analog with a unique mechanism of protracted action designed to reduce the variability associated with conventional basal insulins. This trial compared the glycemic control, risk of hypoglycemia, and effect on body weight of insulin detemir and NPH insulin in patients with type 1 diabetes treated with rapid-acting insulin aspart at meals.

RESEARCH DESIGN AND METHODS—This study was a 6-month multinational open parallel-group comparison conducted at 46 centers in five countries and included 448 patients with type 1 diabetes randomized 2:1 to insulin detemir or NPH insulin, respectively.

RESULTS—After 6 months, comparable HbA_1c levels were found between the two treatment groups. Fasting plasma glucose tended to be lower in patients treated with insulin detemir, but this difference was not statistically significant (-0.76 mmol/l, P = 0.097). Within-subject variation in self-measured fasting blood glucose was lower with insulin detemir than with NPH insulin (SD 3.37 vs. 3.78 mmol/l, P < 0.001). Risk of hypoglycemia was 22% lower with insulin detemir than with NPH insulin (P < 0.05) and 34% lower for nocturnal (2300–0600) hypoglycemia (P < 0.005). Nightly plasma glucose profiles were smoother and more stable with insulin detemir (P = 0.05). Body weight was significantly lower with insulin detemir at the end of the trial (P < 0.001).

CONCLUSIONS—Treatment with insulin detemir resulted in more predictable glycemic control, with smoother plasma glucose profiles than NPH insulin and a significant reduction in the risk of hypoglycemia. The reduction in body weight with insulin detemir is a potential additional advantage. Regimens optimized for insulin detemir may be able to improve glycemic control beyond that possible with NPH insulin.

Abbreviations: DCCT, Diabetes Control and Complications Trial • FPG, fasting plasma glucose • IAsp, insulin aspart • SMBG, self-measured blood glucose

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Dagdelen, L. L. Ilag, S. Martin, S. J. Jacober, R. R. Holman, A. J. Farmer, M. J. Davies, G. T. McMahon, and R. G. Dluhy Addition of insulin to oral therapy in type 2 diabetes. N. Engl. J. Med., March 13, 2008; 358(11): 1197 - 1198. [Full Text] [PDF]

				S. Shalitin and M. Phillip Hypoglycemia in Type 1 Diabetes: A still unresolved problem in the era of insulin analogs and pump therapy Diabetes Care, February 1, 2008; 31(Supplement_2): S121 - S124. [Abstract] [Full Text] [PDF]

				M. J. Fowler Diabetes Treatment, Part 3: Insulin and Incretins Clin. Diabetes, January 1, 2008; 26(1): 35 - 39. [Full Text] [PDF]

				F. Porcellati, P. Rossetti, N. R. Busciantella, S. Marzotti, P. Lucidi, S. Luzio, D. R. Owens, G. B. Bolli, and C. G. Fanelli Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study Diabetes Care, October 1, 2007; 30(10): 2447 - 2452. [Abstract] [Full Text] [PDF]

				M. C. Jones and M. Patel Insulin detemir: A long-acting insulin product Am. J. Health Syst. Pharm., December 15, 2006; 63(24): 2466 - 2472. [Abstract] [Full Text] [PDF]

				B. Keymeulen, P. Gillard, C. Mathieu, B. Movahedi, G. Maleux, G. Delvaux, D. Ysebaert, B. Roep, E. Vandemeulebroucke, M. Marichal, et al. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft PNAS, November 14, 2006; 103(46): 17444 - 17449. [Abstract] [Full Text] [PDF]

				C. Carver Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes The Diabetes Educator, November 1, 2006; 32(6): 910 - 917. [Abstract] [Full Text] [PDF]

				F. M Regan and D. B Dunger Use of new insulins in children Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53. [Full Text] [PDF]

				K. Hermansen, M. Davies, T. Derezinski, G. Martinez Ravn, P. Clauson, P. Home, and on behalf of the Levemir Treat-to-Target Study Gro A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. Diabetes Care, June 1, 2006; 29(6): 1269 - 1274. [Abstract] [Full Text] [PDF]

				J. Meece Dispelling Myths and Removing Barriers About Insulin in Type 2 Diabetes The Diabetes Educator, January 1, 2006; 32(1): 9S - 18S. [Full Text] [PDF]

				J. Plank, M. Bodenlenz, F. Sinner, C. Magnes, E. Gorzer, W. Regittnig, L. A. Endahl, E. Draeger, M. Zdravkovic, and T. R. Pieber A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog Detemir Diabetes Care, May 1, 2005; 28(5): 1107 - 1112. [Abstract] [Full Text] [PDF]

				J. D Goldman-Levine and K. W Lee Insulin Detemir--A New Basal Insulin Analog Ann. Pharmacother., March 1, 2005; 39(3): 502 - 507. [Abstract] [Full Text] [PDF]

				I. B. Hirsch Insulin Analogues N. Engl. J. Med., January 13, 2005; 352(2): 174 - 183. [Full Text] [PDF]

				P. Home, P. Bartley, D. Russell-Jones, H. Hanaire-Broutin, J.-E. Heeg, P. Abrams, M. Landin-Olsson, B. Hylleberg, H. Lang, and E. Draeger Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes: A randomized clinical trial Diabetes Care, May 1, 2004; 27(5): 1081 - 1087. [Abstract] [Full Text] [PDF]

				T. Danne, K. Lupke, K. Walte, W. von Schuetz, and M.-A. Gall Insulin Detemir Is Characterized by a Consistent Pharmacokinetic Profile Across Age-Groups in Children, Adolescents, and Adults With Type 1 Diabetes Diabetes Care, November 1, 2003; 26(11): 3087 - 3092. [Abstract] [Full Text] [PDF]